A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)
← catalyst calendarNCT06730061 · readout in 120 d
Sponsored by Ipsen (industry) · IPN.PA — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
18actual
Sites
16
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-16 | actual | When the study began enrolling |
| Primary completion | 2026-12-17 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-04-08 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Primary Biliary Cholangitis
Intervention
- Drug: Elafibranor
Primary outcome
what the primary-completion date above is the date OFPercentage of participants with Alkaline phosphatase (ALP) <1.67x ULN, ALP decrease ≥15% and Total Bilirubin (TB) ≤ ULN
measured At Week 52
Permalink · IPN.PA's whole pipeline · Catalyst calendar · Every registered study · What changed